EUROHELICAN-The First Helicobacter Pylori Screen-and-Treat Population-Based Study in Young Adults in Europe - PubMed
5 hours ago
- #gastric cancer prevention
- #population-based study
- #Helicobacter pylori
- EUROHELICAN is the first Helicobacter pylori (H. pylori) screen-and-treat population-based study in young adults (30-34 years) in Europe.
- The study aimed to assess the feasibility, acceptability, effectiveness, and adverse events of an H. pylori screen-and-treat program.
- 2102 participants were tested; the response rate was 24.4%, higher in women (28.1%) than men (20.5%).
- Serological prevalence of H. pylori infection was 14.2%, with 83.7% confirmed by urea breath test (UBT).
- A 14-day bismuth-based quadruple therapy achieved an eradication rate of 94.7%.
- Adverse events were more frequent in women (38.8%) than men (21.5%).
- The study concluded that H. pylori screening and treatment in Slovenia is feasible and effective, with acceptable adverse event rates.
- Public awareness efforts are needed to improve participation rates.